Navigation Links
Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
Date:3/17/2009

Issuance Will Give Company Patents in Each of the Three Critical Areas of RNAi Therapeutic Development

PALO ALTO, Calif., March 17 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance for a patent covering various aspects of a potent small interfering RNA (siRNA) sequence. The allowed subject matter covers a specific double-stranded siRNA sequence that is directed against the angiogenic pathway and which possesses therapeutic potential in the treatment of cancer. This notice of allowance pertains to the first of a number of pending patent applications covering proprietary Intradigm siRNA sequences against more than 50 clinically relevant targets.

As the first sequence-specific patent for which Intradigm has received a notice of allowance, this development supplements the company's existing patents, giving Intradigm allowed intellectual property (IP) covering each of the three critical areas for RNAi therapeutic development: target sequences, delivery and structural features. This breadth of intellectual property places Intradigm in a uniquely strong position within the RNAi therapeutic industry, especially among other private companies in the space.

"The receipt of this notice of allowance provides us a great deal of confidence in our ability to successfully prosecute our large number of pending sequence patents and, in turn, build one of the industry's strongest siRNA sequence patent positions," said Philip Haworth, chief executive officer of Intradigm. "Additionally, once this patent issues, Intradigm will possess issued patents related to siRNA sequences, siRNA delivery technology and siRNA structural motifs. We believe this breadth of coverage provides the company with a key competitive advantage in the RNAi therapeutics space."

ABOUT INTRADIGM

Intradigm is a private biotechnology company committed to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. Intradigm is unique among private companies, with its comprehensive RNAi therapeutics platform consisting of structural features for next-generation RNAi molecules, biodegradable polycationic polymers for the delivery of RNAi therapeutics and proprietary siRNA sequence applications. Our proprietary delivery technology is unique in its potential to offer safe and effective systemic administration using a library of novel peptide-based biodegradable polymers.

We have established an impressive proprietary portfolio of siRNA sequences against more than 50 highly valued oncology and other disease targets. In addition, we have secured an exclusive license to the Zamore patent family from the University of Massachusetts, which covers broad structural features of siRNA design for more potent next-generation siRNA sequences. Our goal is to grow Intradigm to become a leading company in enabling the development of novel RNAi therapeutics against a broad range of therapeutic targets using our siRNA sequences and delivery technology.

For more information on Intradigm, please visit www.intradigm.com.


'/>"/>
SOURCE Intradigm Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intradigm Closes Final Tranche of $21.4 Million Series B Financing
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
4. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
5. Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome
6. Catilin Receives Renewable Energy Award for Pilot Plant
7. Avon Protection Systems Receives NIOSH Approval for ST53 SCBA System
8. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
9. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
10. AMPAC Fine Chemicals Receives the California Pollution Prevention Challenge Award Two Consecutive Years
11. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):